Search Result

Results for "

NVP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Anaplastic lymphoma kinase (ALK) (2) Antibiotic (1) Apoptosis (42) Autophagy (18) Bacterial (1) Bcr-Abl (1) Bradykinin Receptor (1) c-Kit (1) c-Met/HGFR (1) Caspase (3) CDK (2) CFTR (1) CXCR (1) Dipeptidyl Peptidase (10) Drug Derivative (1) Drug Isomer (2) Drug Metabolite (1) E1/E2/E3 Enzyme (3) EGFR (2) Ephrin Receptor (2) FAK (3) Ferroptosis (7) FGFR (5) FLT3 (1) Folate Receptor (FR) (1) Glucokinase (2) HDAC (9) HIF/HIF Prolyl-Hydroxylase (1) HIV (9) HSP (4) IGF-1R (7) iGluR (3) IKZF Family (1) Insulin Receptor (7) Interleukin Related (1) Isotope-Labeled Compounds (9) JAK (5) Kinesin (1) MDM-2/p53 (7) Microtubule/Tubulin (1) Molecular Glues (1) mTOR (7) NOD-like Receptor (NLR) (1) Parasite (6) PARP (1) PCSK9 (1) PDGFR (1) PERK (3) Phosphodiesterase (PDE) (1) PI3K (14) PI4K (1) PPAR (1) Prostaglandin Receptor (3) Pyk2 (2) Ras (3) Reference Standards (17) RET (2) Reverse Transcriptase (3) SARS-CoV (1) Smo (4) Sodium Channel (1) STAT (2) Tie (1) VEGFR (4) Virus Protease (1)
By Research Areas:	Cancer (85) Cardiovascular Disease (2) Endocrinology (6) Infection (16) Inflammation/Immunology (12) Metabolic Disease (15) Neurological Disease (6)

By Targets:

ADC Payload (1)

Anaplastic lymphoma kinase (ALK) (2)

Antibiotic (1)

Apoptosis (42)

Autophagy (18)

Bacterial (1)

Bcr-Abl (1)

Bradykinin Receptor (1)

c-Kit (1)

c-Met/HGFR (1)

Caspase (3)

CDK (2)

CFTR (1)

CXCR (1)

Dipeptidyl Peptidase (10)

Drug Derivative (1)

Drug Isomer (2)

Drug Metabolite (1)

E1/E2/E3 Enzyme (3)

EGFR (2)

Ephrin Receptor (2)

FAK (3)

Ferroptosis (7)

FGFR (5)

FLT3 (1)

Folate Receptor (FR) (1)

Glucokinase (2)

HDAC (9)

HIF/HIF Prolyl-Hydroxylase (1)

HIV (9)

HSP (4)

IGF-1R (7)

iGluR (3)

IKZF Family (1)

Insulin Receptor (7)

Interleukin Related (1)

Isotope-Labeled Compounds (9)

JAK (5)

Kinesin (1)

MDM-2/p53 (7)

Microtubule/Tubulin (1)

Molecular Glues (1)

mTOR (7)

NOD-like Receptor (NLR) (1)

Parasite (6)

PARP (1)

PCSK9 (1)

PDGFR (1)

PERK (3)

Phosphodiesterase (PDE) (1)

PI3K (14)

PI4K (1)

PPAR (1)

Prostaglandin Receptor (3)

Pyk2 (2)

Ras (3)

Reference Standards (17)

RET (2)

Reverse Transcriptase (3)

SARS-CoV (1)

Smo (4)

Sodium Channel (1)

STAT (2)

Tie (1)

VEGFR (4)

Virus Protease (1)

By Research Areas:

Cancer (85)

Cardiovascular Disease (2)

Endocrinology (6)

Infection (16)

Inflammation/Immunology (12)

Metabolic Disease (15)

Neurological Disease (6)

121

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Antibodies

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10224

Panobinostat 80+ Cited Publications LBH589; NVP-LBH589	HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities . Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells . Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma .

HY-13311

Infigratinib 45+ Cited Publications BGJ-398; NVP-BGJ398	FGFR Apoptosis	Cancer
Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC₅₀s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-50673

Dactolisib 65+ Cited Publications BEZ235; NVP-BEZ235	PI3K mTOR Autophagy	Cancer
Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC₅₀s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.

HY-70063

Buparlisib Maximum Cited Publications 88 Publications Verification BKM120; NVP-BKM120	PI3K Apoptosis	Cancer
Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with blood-brain barrier permeability. Buparlisib has IC₅₀s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively .

HY-10570

Nevirapine 5+ Cited Publications BI-RG 587; NSC 641530; NVP	HIV Reverse Transcriptase Parasite	Infection Cancer
Nevirapine is a non-nucleoside inhibitor of HIV-1 reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM .

HY-14291

Vildagliptin 5 Publications Verification LAF237; NVP-LAF 237	Dipeptidyl Peptidase Ferroptosis Apoptosis	Metabolic Disease Cancer
Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-10215

Luminespib 20+ Cited Publications VER-52296; AUY922; NVP-AUY922	HSP Autophagy Apoptosis	Cancer
Luminespib (VER-52296) is a potent HSP90 inhibitor with IC₅₀s of 7.8 and 21 nM for HSP90α and HSP90β, respectively .

HY-15190

NVP-HSP990 4 Publications Verification HSP-990	HSP Apoptosis	Cancer
NVP-HSP990 is a potent, selective and orally active Hsp90 inhibitor, with IC₅₀ values of 0.6, 0.8, and 8.5 nM for Hsp90α, Hsp90β, and Grp94, respectively.

HY-12214A

NVP-2 40+ Cited Publications	CDK Apoptosis	Cancer
NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC₅₀ of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC₅₀ values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces cell apoptosis.

HY-155876

NVP-DFV890 NLRP3 antagonist 2	NOD-like Receptor (NLR)	Infection Inflammation/Immunology
NVP-DFV890 is an orally administered, selective NLRP3 inhibitor. NVP-DFV890 directly binds to NLRP3, blocks maturation of pro-inflammatory cytokines IL-1β and IL-18, and inhibits pyroptotic cell death. NVP-DFV890 acts as an inducer of viral clearance, promoting earlier clearance of SARS-CoV-2. NVP-DFV890 can be used for the research of COVID-19 pneumonia and coronavirus-associated acute respiratory distress syndrome (CARDS) .

HY-144998

NVP-DKY709 1 Publications Verification	IKZF Family Molecular Glues	Inflammation/Immunology Cancer
NVP-DKY709 is an orally active and selective IKZF2 molecular glue degrader with the D_max and DC₅₀ of 53% and 4 nM, respectively. In addition, NVP-DKY709 can degrade IKZF4 (DC₅₀: 13 nM) and SALL4 (DC₅₀: 2 nM). NVP-DKY709 exerts anti-tumor activity by binding with CRBN to change conformation and recruit and degrade IKZF2 .

HY-50866

NVP-AEW541 10+ Cited Publications AEW541	IGF-1R Insulin Receptor Autophagy	Endocrinology Cancer
NVP-AEW541 (AEW541 ) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC₅₀ value of 0.15 μM. NVP-AEW541 also inhibits InsR, IC₅₀ with a value of 0.14 μM. NVP-AEW541 has antitumor activity .

HY-18658

Siremadlin 10+ Cited Publications NVP-HDM201; HDM201	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Siremadlin (NVP-HDM201) is a potent, orally bioavailable and highly specific p53-MDM2 interaction inhibitor.

HY-13258A

NVP-BHG712 5+ Cited Publications BHG712	Ephrin Receptor	Cancer
NVP-BHG712 is an oral active EphB4 kinase autophosphorylation inhibitor, with IC₅₀ values of 3.3 nM and 3.0 nM for EphA2 and EphB4, respectively .

HY-13606

Dacinostat 5+ Cited Publications NVP-LAQ824; LAQ824	HDAC Autophagy	Cancer
Dacinostat is a potent HDAC inhibitor, with an IC₅₀ of 32 nM; Dacinostat also inhibits HDAC1 with an IC₅₀ of 9 nM, and used in cancer research.

HY-13945

NVP 231 3 Publications Verification	Apoptosis	Cancer
NVP 231 is a potent, specific, and reversible ceramide kinase (CerK) inhibitor(IC₅₀=12 nM) that competitively inhibits binding of ceramide to CerK . NVP 231 induces cell apoptosis by increasing DNA fragmentation and caspase-3 and caspase-9 cleavage .

HY-13203

NVP-TAE 226 5+ Cited Publications TAE226	FAK Pyk2 IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC₅₀s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC₅₀s of 3.5 nM and 44 nM, respectively .

HY-10192

NVP-TAE 684 10+ Cited Publications TAE 684	Anaplastic lymphoma kinase (ALK) Apoptosis	Cancer
NVP-TAE 684 (TAE 684) is a highly potent and selective ALK inhibitor, which blocks the growth of ALCL-derived and ALK-dependent cell lines with IC₅₀ values between 2 and 10 nM .

HY-15174

Dactolisib Tosylate 65+ Cited Publications BEZ235 Tosylate; NVP-BEZ 235 Tosylate	PI3K mTOR Autophagy	Cancer
Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC₅₀ values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

HY-15002

AST 487 5 Publications Verification NVP-AST 487	RET FLT3 VEGFR c-Kit Bcr-Abl	Cancer
AST 487 is a RET kinase inhibitor with IC₅₀ of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC₅₀ of 520 nM.

HY-18840

BBT594 2 Publications Verification NVP-BBT594	RET	Cancer
BBT594 is a potent receptor tyrosine kinase RET inhibitor, used for cancer treatment.

HY-16582A

Sonidegib 10+ Cited Publications Erismodegib; LDE225; NVP-LDE225	Smo	Cancer
Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC₅₀ of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively .

HY-15954

NVP-CGM097 3 Publications Verification CGM097	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
NVP-CGM097 is a potent and selective MDM2 inhibitor with IC₅₀ of 1.7±0.1 nM for hMDM2.

HY-13990

NVP-TNKS656 TNKS656	PARP Apoptosis	Cancer
NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC₅₀ of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.

HY-139612

Opnurasib 5+ Cited Publications JDQ-443; NVP-JDQ443	Ras PERK	Inflammation/Immunology Cancer
Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor. Opnurasib shows antitumor activity .

HY-16768

Fevipiprant 1 Publications Verification QAW039; NVP-QAW039	Prostaglandin Receptor	Cardiovascular Disease
Fevipiprant (QAW039, NVP-QAW039) is s an orally active, selective, reversible prostaglandin D2 (DP2) receptor antagonist with an K_d value of 1.14 nM. Fevipiprant has the potential for the research of bronchial asthma .

HY-13334A

BGT226 5 Publications Verification NVP-BGT226	PI3K mTOR Autophagy	Cancer
BGT226 (NVP-BGT226) is a PI3K (with IC₅₀s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells .

HY-10045

AEE788 3 Publications Verification NVP-AEE 788	EGFR Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
AEE788 is an orally active inhibitor targeting EGFR and ErbB2 with IC₅₀ values of 2 and 6 nM, respectively ^[1][2][3].

HY-10252

NVP-ADW742 3 Publications Verification ADW742; GSK 552602A; ADW	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC₅₀ of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC₅₀ of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells .

HY-14722A

NVP-BSK805 dihydrochloride 3 Publications Verification	JAK	Cancer
NVP-BSK805 dihydrochloride is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-14722

NVP-BSK805 3 Publications Verification	JAK	Cancer
NVP-BSK805 is an ATP-competitive JAK2 inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-13311A

Infigratinib phosphate 45+ Cited Publications BGJ-398 phosphate; NVP-BGJ398 phosphate	FGFR	Cancer
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC₅₀ of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-10942

VER-82576 5 Publications Verification NVP-BEP800	HSP	Cancer
VER-82576 (NVP-BEP800) is a potent, orally available and selective Hsp90 inhibitor, with an IC₅₀ of 58 nM for Hsp90β; VER-82576 also slightly blocks Grp94 and Trap-1, with IC₅₀s of 4.1 and 5.5 μM, respectively.

HY-13334

BGT226 maleate 5 Publications Verification NVP-BGT226 maleate	PI3K mTOR Autophagy Apoptosis	Cancer
BGT226 (NVP-BGT226 maleate) is a PI3K (with IC₅₀s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells .

HY-15180

Buparlisib Hydrochloride Maximum Cited Publications 88 Publications Verification BKM120 Hydrochloride; NVP-BKM120 Hydrochloride	PI3K Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Buparlisib Hydrochloride (BKM120 Hydrochloride) is a CNS-penetrant pan-class I PI3K inhibitor, with IC₅₀ of 52 nM/166 nM/116 nM/262 nM for p110α/p110β/p110δ/p110γ, respectively.

HY-P11024

NVP-EVS459	Folate Receptor (FR)	Cancer
NVP-EVS459 is a Folate Receptor (FR)-targeting radioconjugate. NVP-EVS459 labeled with 177Lu can be used for tumor diagnosis and research .

HY-13258

NVP-BHG712 isomer 2 Publications Verification	Ephrin Receptor	Cancer
NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4 .

HY-15241

NVP-LCQ195 LCQ-195; AT9311	CDK	Cancer
NVP-LCQ195 (LCQ-195) is an inhibitor of CDK1/2/3/5/9. NVP-LCQ195 induces cell cycle arrest and eventual apoptotic cell death of multiple myeloma (MM) cells. NVP-LCQ195 triggers decreased amplitude of transcriptional signatures related to oncogenesis, drug resistance and stem cell renewal in MM cell lines .

HY-100394

NVP-BAW2881 BAW2881	Tie VEGFR	Endocrinology Cancer
NVP-BAW2881 (BAW2881) is a potent and selective VEGFR2 inhibitor with an IC₅₀ of 9 nM .

HY-P99872

Ecleralimab CSJ-117; NVP-CSJ117	Interleukin Related	Inflammation/Immunology
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP). Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma .

HY-13333

NVP-BAG956 BAG 956	PI3K	Cancer
NVP-BAG956 is an ATP-competitive PI3K inhibitor with IC50s of 34, 56, 112 and 444 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.

HY-148860

NVP-DFF332 HIF-2α-IN-8	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-8 is a potent and orally active HIF2α inhibitor with IC₅₀ values of 9, 37, 246 nM for HIF2α SPA, HIF2α iScript, HIF2α HRE RGA, respectively. HIF-2α-IN-8 shows antitumor activity .

HY-19624

NVP-ACC789 ACC-789; ZK202650	VEGFR PDGFR	Cancer
NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.

HY-12294A

PEAQX tetrasodium hydrate 5+ Cited Publications NVP-AAM077 tetrasodium hydrate	Apoptosis Caspase iGluR	Neurological Disease
PEAQX tetrasodium hydrate (NVP-AAM077 tetrasodium hydrate) is a tetrasodium hydrate of PEAQX (HY-12294). PEAQX tetrasodium hydrate is an orally active and selective NMDA antagonist, with IC₅₀ values of 270 nM and 29.6 μM for hNMDAR 1A/2A and hNMDAR 1A/2B, respectively. PEAQX tetrasodium hydrate can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .

HY-15456

NVP-BVU972	c-Met/HGFR	Cancer
NVP-BVU972 is an selective and potent Met inhibitor, with an IC₅₀ of 14 nM. NVP-BVU972 also exhibits good anti-proliferative activity against Met with drug-resistant mutations and inhibits phosphorylation. NVP-BVU972 can be used in study of cancer .

HY-15954B

NVP-CGM097 sulfate 3 Publications Verification CGM097 sulfate	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
NVP-CGM097 sulfate is a potent and selective MDM2 inhibitor with IC₅₀ of 1.7±0.1 nM for hMDM2.

HY-12294

PEAQX NVP-AAM077	Caspase Apoptosis iGluR	Neurological Disease
PEAQX (NVP-AAM077) is an orally active and selective NMDA antagonist, with IC₅₀ values of 270 nM and 29.6 μM for hNMDAR 1A/2A and hNMDAR 1A/2B, respectively. PEAQX can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .

HY-18636

LEQ506 NVP-LEQ506	Smo	Cancer
LEQ506 is a second-generation inhibitor of smoothened (Smo) with IC₅₀s of 2 and 4 nM in human and mouse, respectively.

HY-10224R

Panobinostat (Standard) 80+ Cited Publications LBH589 (Standard); NVP-LBH589 (Standard)	Reference Standards HDAC Autophagy HIV Apoptosis	Infection Cancer
Panobinostat (Standard) (LBH589 (Standard)) is the analytical standard of Panobinostat (HY-10224). This product is intended for research and analytical applications. Panobinostat is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities . Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells . Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma .

HY-177285

NVP-BQS481	Kinesin ADC Payload	Cancer
NVP-BQS481 (Compound 1) is a selective Kinesin spindle protein-5 (Eg5) inhibitor with an IC₅₀< 0.5 nM. NVP-BQS481 has significant antimitotic and antitumor activity (IC₅₀: 0.0.9 nM for SK-OV-3ip cells). NVP-BQS481 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs) .

Cat. No.	Product Name	Target	Research Area

HY-P11024

NVP-EVS459	Folate Receptor (FR)	Cancer
NVP-EVS459 is a Folate Receptor (FR)-targeting radioconjugate. NVP-EVS459 labeled with 177Lu can be used for tumor diagnosis and research .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99872

Ecleralimab CSJ-117; NVP-CSJ117	Interleukin Related	Inflammation/Immunology
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP). Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma .

HY-P99251

Lodelcizumab LGT209; NVP-LGT209	PCSK9	Others
Lodelcizumab is a monoclonal antibody targeting PCSK9. Lodelcizumab can be used for the research of hypercholesterolemia .

Cat. No.	Product Name	Chemical Structure

HY-10224S1

Panobinostat-d4 hydrochloride

Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S

Panobinostat-d4

Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-14291S2

Vildagliptin-13C5,15N
Vildagliptin- ¹³C₅, ¹⁵N (LAF237- ¹³C₅, ¹⁵N; NVP-LAF 237- ¹³C₅, ¹⁵N) is a ¹³C- and ¹⁵N-labeled Vildagliptin (HY-14291). Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-13311S

Infigratinib-d3
Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the FGFR family, with IC₅₀ values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively .

HY-14291S

Vildagliptin-d3
Vildagliptin-d₃ is the deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-14291S1

Vildagliptin-d7
Vildagliptin-d₇ is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-132530S

NVP-BEZ 235-d3
NVP-BEZ 235-d3 is the deuterium labeled NVP-BEZ 235 .

HY-14291S5

Vildagliptin-d6
Vildagliptin-d₆ (LAF237-d₆ ) is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC₅₀ of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity .

HY-10570S2

Nevirapine-d8
Nevirapine-d₈ (BI-RG 587-d₈) is deuterium labeled Nevirapine. Nevirapine is a non-nucleoside inhibitor of HIV-1 reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM .

HY-16582AS

Sonidegib-d4
Sonidegib-d4 is a isotope of Sonidegib. Sonidegib is a potent and selective Smo antagonist with IC₅₀ of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively .

HY-10570S3

Nevirapine-d5
Nevirapine-d₅ (BI-RG 587-d₅) is deuterium labeled Nevirapine. Nevirapine is a non-nucleoside inhibitor of HIV-1 reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87142

	VILIP1 Antibody (YA6835) 21 kDa CABP antibody; Hippocalcin like protein 3 antibody; Hippocalcin-like protein 3 antibody; HLP 3 antibody; HLP3 antibody; HPCAL 3 antibody; HPCAL3 antibody; HUVISL1 antibody; Neural visinin-like protein 1 antibody; Neural visinin-like type 1 protein antibody; 21 kDa CABP antibody; Hippocalcin like protein 3 antibody; Hippocalcin-like protein 3 antibody; HLP 3 antibody; HLP3 antibody; HPCAL 3 antibody; HPCAL3 antibody; HUVISL1 antibody; Neural visinin-like protein 1 antibody; Neural visinin-like type 1 protein antibody; Neurocalcin alpha antibody; NVL 1 antibody; NVL1 antibody; NVP1 antibody; OZ1 antibody; RatNVP1 antibody; VIL; IP : antibody; VILIP-1 antibody; Visinin antibody; Visinin like 1 antibody; Visinin like protein 1 antibody; Visinin-like protein 1 antibody; VISL 1 antibody; VISL1 antibody; VISL1_HUMAN antibody; VLP-1 antibody; Vnsl1 antibody; Vsnl1 antibody;	WB, IHC-P	Human, Mouse, Rat
	VILIP1 Antibody (YA6835) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VILIP1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13990G

NVP-TNKS656 TNKS656	PPAR Apoptosis	Cancer
NVP-TNKS656 (GMP) is NVP-TNKS656 (HY-13990) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC₅₀ of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: